French biopharmaceutical company seeks licensing partners and investors for Phase 2-ready RIPK2 (Receptor-interacting serine/threonine-protein kinase 2) inhibitor in inflammatory bowel disease

Summary

Profile type

Technology offer

Company's country

France

POD reference

TOFR20250929004

Profile status

PUBLISHED

Type of partnership

Investment agreement

Commercial agreement with technical assistance

Targeted countries

- **Netherlands**
- **Germany**
- **Hungary**
- **Slovakia**
- **Greece**
- **Estonia**
- **Slovenia**
- **United Kingdom**
- **Finland**
- **Romania**
- **Canada**
- **Denmark**
- **Australia**
- **France**
- **Lithuania**
- **Cyprus**
- **Sweden**
- **Portugal**
- **Latvia**
- **Japan**

- **Ireland**
- **Luxembourg**
- **Italy**
- **Belgium**
- **Bulgaria**
- **Poland**
- **Austria**
- **China**
- **United States**
- **Spain**
- **Croatia**
- **Malta**

Contact Person	Term of validity	Last update
Noriko MITA	**29 Sep 2025** **29 Sep 2026**	**29 Sep 2025**

General Information

Short summary

A French precision medicine biotech is offering a licensing, selling or investment opportunity for its Phase 2–ready small molecule inhibitor of RIPK2. The molecule has completed successful first-in-human studies in healthy volunteers, strong intellectual property and a strong Pharmacokinetics /Pharmacodynamics relationship. It represents a highly de-risked opportunity for inflammatory bowel disease. Industrial partners are sought to continue its development - regulatory and clinical strategy.

Full description

This French precision medicine biotech is a spin-off launched in 2022 from a 25+ year successful oncology service company. It specializes in precision medicine for oncology, inflammation, and neurology, leveraging proprietary platforms including kinase inhibitor design, AI-driven target identification, and radioligand therapies.

The inflammatory bowel disease (IBD) therapy market is rapidly growing, projected at $25–27B in 2025 and $40–45B by 2030–2034, driven by rising Crohn’s and ulcerative colitis cases, better diagnostics, and awareness. Despite many available treatments, major unmet needs persist: chronic symptoms, relapses, poor quality of life, surgery risk, and limited options for patients unresponsive to current biologics or small molecules. Long-term remission, fewer side effects, and more reliable responses remain key goals.

NOD2 is an intracellular innate immune sensor involved in host defense and Crohn's disease. Receptor-interacting serine/threonine-protein kinase 2 (RIPK2), a key kinase in the NOD2 pathway is overexpressed

in inflamed IBD tissue and drives cytokines like TNF-α and IL-12/23.
Preclinical and early clinical data show RIPK2 inhibitors reduce intestinal inflammation and pathogenic signaling, offering a targeted oral therapy with fewer systemic effects. They represent a promising class with potential for efficacy, tolerability, and durable remission, especially in patients unresponsive to current treatments.

With 14 staff and strong ties with academic and hospital ecosystems, the biotech company has developed a small molecule inhibitor of RIPK2 named "OPM-101". The asset has completed successful first-in-human studies in healthy volunteers, has strong intellectual property protection, GMP (Good Manufacturing Practices) process in place. OPM-101 represents a phase-2 ready disease-modifying therapy in the IBD's field.

The company is now looking for partners to license out the intellectual property, with a potential interest for selling out the full asset for a worldwide diffusion in IBD.
Partners with expertise in IBD clinical development are specially targeted.

Advantages and innovations

The molecule named OPM-101 has several features such as :

- Compound class: Small-molecule, highly selective orally available RIPK2 inhibitor
- Mechanism: Selective NOD2/RIPK2 pathway inhibition
- Indication: Inflammatory Bowel Disease (IBD): Ulcerative Colitis, Crohn's Disease
- Clinical Phase: Phase 1 complete (Single Ascending Dose & Multiple Ascending Dose)
- Pharmacokinetics profile: Rapid absorption, long half-life
- Safety: Excellent; no serious adverse events
- Target engagement: Robust, sustained TNF-α inhibition at low doses
- Key differentiator: Immunomodulation, not broad immunosuppression

Technical specification or expertise sought

Stage of development

Under development

IPR Status

IPR granted

IPR Notes

Sustainable Development goals

- **Goal 3: Good Health and Well-being**

Partner Sought

Expected role of the partner

Partners will continue the development of OPM-101 in IBD, taking over the regulatory and clinical strategy, lead patient recruitment, and collaborate on biomarker-led patient selection. They are open to joint IP development, regional licensing, and revenue-sharing agreements.

Type of partnership

Investment agreement

Commercial agreement with technical assistance

Type and size of the partner

- **SME <=10**
- **Other**
- **SME 11-49**
- **Big company**
- **SME 50 - 249**

Dissemination

Technology keywords

- **06001015 - Pharmaceutical Products / Drugs**
- **06001003 - Cytology, Cancerology, Oncology**

Market keywords

- **05007002 - Pharmaceuticals/fine chemicals**

Targeted countries

- **Netherlands**
- **Germany**
- **Hungary**
- **Slovakia**
- **Greece**
- **Estonia**
- **Slovenia**
- **United Kingdom**
- **Finland**
- **Romania**
- **Canada**
- **Denmark**
- **Australia**
- **France**
- **Lithuania**
- **Cyprus**
- **Sweden**
- **Portugal**
- **Latvia**
- **Japan**
- **Ireland**
- **Luxembourg**
- **Italy**
- **Belgium**
- **Bulgaria**
- **Poland**
- **Austria**
- **China**
- **United States**
- **Spain**

Sector groups involved

- **Health**

- **Croatia**
- **Malta**